No Data
No Data
JMP Securities Initiates Nuvation Bio(NUVB.US) With Buy Rating, Announces Target Price $6
JMP Securities Initiates Coverage On Nuvation Bio With Market Outperform Rating, Announces Price Target of $6
Press Release: Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025
Express News | Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025
Optimistic Outlook for Nuvation Bio: Strategic Positioning and Market Potential of Taletrectinib
Insider Purchase: PRESIDENT AND CEO of $NUVB Buys 300,000 Shares
Sheldon Yu : Agree
Stock_Drift : Bullish.

$Nuvation Bio (NUVB.US)$